Latest Breaking News On - Peloton therapeutics - Page 1 : comparemela.com

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
bmj.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bmj.com Daily Mail and Mail on Sunday newspapers.

United statesEteläuomen läiSouth koreaJin wangGenentechf hoffmannAsher biotherapeuticsDaiichi sankyoChipscreen biosciencesBristol myers squibbAshfield medcommsMerck biopharmMerck seronoSamsung bioepisLyell immunopharmaCalithera biosciencesEli lilly

Drug targeting clear cell renal cell carcinoma shows promising approach

In a groundbreaking phase one clinical trial led by UT Southwestern Medical Center, a short interfering RNA (siRNA) drug directed to tumor cells effectively di

United statesRobert lewis kirbyNizarm tannirJames brugarolasDivision of hematologySherry wigley crow cancer researchSimmons cancer centerSouthwestern medical centerKidney cancer programArrowhead pharmaceuticalsClinical cancer researchNational cancer instituteKidney cancer specialized program of research excellenceHaroldc simmons comprehensive cancer centerBrugarolas labUniversity of texas md anderson cancer center

Adjuvant Pembrolizumab Significantly Prolongs OS vs Placebo in ccRCC

Treatment with adjuvant pembrolizumab significantly improved overall survival vs placebo in patients with clear cell renal cell carcinoma.

United statesDana farber cancer instituteBristol myers squibbNancy kohlbergToni choueiriRoche genentechCalithera biosciencesSanofi aventisMichaelj hennessy associatesGilead sciencesInfinity pharmaceuticalsLank centerKidney cancer programMedicine at harvard medical schoolFoundation medicineNavinata health

Texas Woman s University and Scottish Rite Partner for Scoliosis Fashion and TRA s New CEO

Plus a UTSW discovery leads to kidney cancer drug and Cook Children's physician wins Global Impact Award.

United statesPaul thorntonMark kalmarTexas radiology associatesTexas woman universityCook children health care systemUt southwestern medical centerTexas womanScottish riteMass production techniquesRadiology associatesPacific imaging consultantsPeloton therapeuticsCook childrenHealth care systemGlobal impact award

FDA approval expands Welireg to patients with renal cell carcinoma

The oral treatment belzutifan, developed by MSD (known as Merck in the US) and branded as Welireg, has received the green light from the US Food and Drug Administration (FDA) for the treatment of an advanced form of renal cell carcinoma (RCC).

Merck research laboratoriesMarjorie greenMerck researchPeloton therapeuticsClinical developmentAtient centricityLinical evolutionTransparency on trialFood and drug administrationFda approval